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Recent work in Cell Reports by Minett et al. and Yang et al. highlights the complexity of pain
pathways and points to new ways of thinking about chronic and disease-related pain.Pain perception helps prevent injury
by inducing appropriate protective re-
sponses such as rapid withdrawal. After
injury, pain thresholds are dramatically
decreased in order to provide injured tis-
sues extra protection from further insults.
Unfortunately, in many clinical conditions,
pain becomes chronic and is no longer
protective. It arises spontaneously, innoc-
uous stimuli become painful (allodynia),
and noxious stimuli evoke an exagger-
ated and prolonged response (hyperalge-
sia) (Latremoliere and Woolf, 2009). It is
estimated that over one-fifth of the
world’s population suffers from persistent
or recurrent pain. Importantly, clinicians
have few, if any, consistently effective
means of relieving chronic pain without
severe side effects.
Neurons of the peripheral nervous
system, namely primary sensory neurons,
have emerged as attractive targets for
novel pharmacological strategies (Julius
and Basbaum, 2001). Most analgesic
drugs (i.e., opioids) are known to influence
nociceptive terminals (Janson and Stein,
2003), and cannabinoid-induced anal-
gesia occurs largely through primary
sensory neurons and not through CNS
neurons (Agarwal et al., 2007). Thus, effi-
cient treatment of pain requires an exten-
sive understanding of primary sensory
neuron physiology and a better knowl-
edge of the mechanisms that operate un-
der pathological conditions to perpetuate
pain perception.
Primary sensory neurons comprise
a highly heterogeneous population with
respect to morphological, anatomical,
molecular, and electrophysiological prop-Cell Reerties (Abraira and Ginty, 2013; Gascon
and Moqrich, 2010; Liu and Ma, 2011).
However, knowledge of the functional sig-
nificance of this remarkable diversity is
just emerging. Indeed, genetic ablation
of neurons expressing the G-protein-
coupled receptorMrgprd leads to a selec-
tive deficit in noxious mechanical pain
sensitivity with no effect on sensation of
noxious heat or cold (Cavanaugh et al.,
2009), whereas pharmacological ablation
of central projections expressing the
heat-sensitive ion channel TRPV1 selec-
tively abolishes noxious heat pain with
no effect on cold or mechanical pain
sensitivity (Cavanaugh et al., 2009). Inter-
estingly, combined ablation of these
two nonoverlapping subsets of neurons
yields an additive phenotype with no
additional behavioral deficit (Cavanaugh
et al., 2009). Consistent with these find-
ings, developmental ablation of neurons
expressing the sodium channel Nav1.8
eliminates nearly all nociceptive neurons,
leading to deficits in cold, mechanical,
and formalin-evoked pain sensitivity
(Abrahamsen et al., 2008). Collectively
these studies demonstrate that molecu-
larly distinguishable subpopulations of
neurons can selectively mediate distinct
responses to different stimuli in a modal-
ity-specific manner.
How is This Modality Specificity
Established?
In a recent issue of Cell Reports, Yang
et al. (2013) provide compelling evidence
for a genetic program that distinguishes
between two topographically distinct
subpopulations of pain-sensing neurons:ports 6, January 30, 2014 ª2014 The AuthorsRUNX1-dependent neurons, which proj-
ect to the epidermis and are mainly
involved in cutaneous pain, and RUNX1-
independent neurons, which innervate
deep tissues such as muscles and
visceral organs and are mostly involved
in deep-tissue pain sensation. Using the
previously generated conditional runx1
knockout mouse model (Chen et al.,
2006), Yang et al. (2013) show that abla-
tion of RUNX1 in the peripheral nervous
system leads to extraordinary upregula-
tion of a variety of deep-tissue-specific
genes and a nearly complete elimina-
tion of all known cutaneous-specific
genes in cutaneous neurons. As a conse-
quence, cutaneous pain-related sensa-
tion is severely impaired in these mice,
whereas deep-tissue pain is not affected.
Correspondingly, forced expression of
RUNX1 leads to a massive loss of expres-
sion of deep-tissue-specific genes that
was accompanied by a marked deficit in
deep-tissue pain. The key findings of this
study are 2-fold: they expand our under-
standing of the molecular logic that gov-
erns primary sensory neuronal diversity,
and they provide further support for the
emerging hypothesis of primary nocicep-
tor subset modality specificity.
Can This Modality Specificity be
Extended to All Models of Chronic
Pain?
In this issue of Cell Reports, Minett et al.
(2014) provide compelling evidence of
the complexity of the roles of primary sen-
sory and sympathetic neurons in chronic
pain. Taking advantage of mouse strains
lacking several voltage-gated sodium245Open access under CC BY-NC-ND license.
channels (Nav), they examined the roles
of Nav1.7, Nav1.3, Nav1.8, and Nav1.9
in four different models of chronic pain:
two models of nerve injury, pain induced
by the chemotherapeutic agent oxalipla-
tin, and bone-cancer-induced pain. Using
cold and mechanical allodynia as behav-
ioral readouts, they convincingly showed
that Nav1.7 acts in a modality-specify
manner. Indeed, targeted ablation of
Nav1.7 in nociceptors attenuated only
acetone-induced cold allodynia in the
chronic constriction injury (CCI) model,
but it had no effect in the sympatheti-
cally-mediated spinal nerve transec-
tion (SNT) model. However, ablation of
Nav1.7 in all dorsal root ganglion (DRG)
neurons attenuated both cold and
mechanical allodynia in the CCI but not
in the SNT model, whereas ablation of
this channel in DRG and sympathetic neu-
rons triggered strong attenuation of cold
and mechanical allodynia in both CCI
and SNT models. Conversely, ablation of
Nav1.7 in DRG and sympathetic neurons
had no effect on oxaliplatin- or bone-can-
cer-induced pain.
The authors also examined the respec-
tive roles of Nav1.3, Nav1.8, and Nav1.9
in these experimental paradigms and
found little contribution of each of these
channels in CCI-mediated cold allodynia
and no role in SNT-, oxaliplatin-, or246 Cell Reports 6, January 30, 2014 ª2014bone-cancer-induced cold or mechanical
allodynia.
The results support the notion of mo-
dality specificity of primary sensory neu-
rons but also point the sensory biology
community to the interesting fact that
a given subset of neurons can be re-
cruited to efficiently respond to one type
of chronic pain while being completely
dispensable for another type of pain.
Minett et al. (2014) propose that efficient
management of pain will require patients’
stratification at both the mechanistic and
the phenotypic levels.
In conclusion, the study by Yang et al.
(2013) consolidates the role of the tran-
scription factor RUNX1 as the master
gene in a hierarchical cascade leading
to nociceptive neuron diversification and
provides further insights into the func-
tional specialization of cutaneous versus
deep tissue nociceptors. The study by
Minett et al. (2014) supports the growing
idea of the modality specificity of noci-
ceptors in some aspects of neuropathic
pain, provides compelling evidence
regarding concomitant roles of nocicep-
tors and sympathetic neurons in other
neuropathic pain states, and highlights
the need for further investigations to iden-
tify the mechanisms that underlie pain
induced by chemotherapeutic agents or
cancer.The Authors Open access under CC BY-NC-ND liceREFERENCES
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